An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting
Biotechnology and Bioengineering · 2024
DOI: 10.1002/bit.28790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2024. Verfasst von Gerald M Cherf und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Receptors, Urokinase Plasminogen Activator. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Urokinase‐type plasminogen activator receptor (uPAR) is overexpressed on tumor cells in multiple types of cancer and contributes to disease progression and metastasis. In this work, we engineered a novel bi‐paratopic uPAR targeting agent by fusing the binding domains of two native uPAR ligands: uPA and vitronectin, with a flexible peptide linker. The linker length was optimized to facilitate simultaneous engagement of both domains to their adjacent epitopes on uPAR, resulting in a high affinity and avid binding interaction. Furthermore, the individual domains were affinity‐matured using yeast surface display and directed evolution, resulting in a bi‐paratopic protein with affinity in the picomolar to femtomolar range. This engineered uPAR targeting agent demonstrated significantly enhanced tumor localization in mouse tumor models compared to the native uPAR ligand and warrants further investigation as a diagnostic and therapeutic agent for cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, Stanford University, Stanford, California, USA.
- Department of Chemical Engineering, Stanford University, Stanford, California, USA.
- Stanford Cancer Institute, Stanford University, Stanford, California, USA.
ORCID-Profile: Jennifer R Cochran
Zitieren
APA
Cherf, G. M., Lee, R. B., Mehta, N., Clifford, C., Torres, K., Kintzing, J. R., & Cochran, J. R. (2024). An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28790
Vancouver
Cherf GM, Lee RB, Mehta N, Clifford C, Torres K, Kintzing JR, et al. An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting. Biotechnology and Bioengineering. 2024. doi:10.1002/bit.28790
BibTeX
@article{Cherf2024,
author = {Cherf, Gerald M and Lee, Robert B and Mehta, Nishant and Clifford, Claire and Torres, Kathleen and Kintzing, James R and Cochran, Jennifer R},
title = {An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting},
journal = {Biotechnology and Bioengineering},
year = {2024},
doi = {10.1002/bit.28790}
}
EUVIMED